A 44-year-old man with diabetes mellitus and alcoholic cirrhosis received intravenous vancomycin for disseminated MRSA infection. Ceftaroline 600 mg intravenously every 8 hours was added on day 6 and stopped on day 54 after eosinophilia of 12%. Ceftaroline was restarted on day 89 at 600 mg intravenously every 12 hours. Linezolid was changed to daptomycin on day 90 because of cytopenias. On day 112, ceftaroline was discontinued after pancytopenia, neutropenia with an ANC of 1472 cells/mm3, and eosinophilia of 10%. By day 116, pancytopenia and eosinophilia had improved. Sullivan EL, Turner RB, O'Neal HR Jr, Crum-Cianflone NF. Ceftaroline-associated neutropenia: case series and literature review of incidence, risk factors, and outcomes. Open Forum Infect Dis. 2019;6(5):ofz168. doi:10.1093/ofid/ofz168. Absolute neutrophil count, initial Initial ANC reported in Table 1; calendar date not reported. Absolute neutrophil count, nadir Reported on study day 112; calendar date not reported. White blood cell count Reported on study day 112; calendar date not reported. Neutrophils Reported on study day 112; calendar date not reported. Eosinophils Reported during the first course on study day 54; calendar date not reported. Eosinophils Reported after re-exposure on study day 112; calendar date not reported. White blood cell count Reported on study day 116; calendar date not reported. Neutrophils Reported on study day 116; calendar date not reported. Neutropenia Eosinophilia Pancytopenia Ceftaroline Vancomycin Linezolid Daptomycin Eva Sullivan Scripps Mercy Hospital Premise Bio demo sender